SCHEMBL25817167

SCHEMBL25817167

Cc1cc(B(O)O)c(OCc2ccccc2)c(C)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 1/20 0.53
PTPN1 P18031 1/20 0.46
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PTGER4 P35408 3/20 0.43
PTGER3 P43115 3/20 0.43
PTGER2 P43116 3/20 0.43
LMNA P02545 3/20 0.42
HPGD P15428 1/20 0.42
PTGER1 P34995 2/20 0.42
ENPP2 Q13822 1/20 0.41
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
GLRA1 P23415 1/20 0.40
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954831 0.79 LIPE (0.62) LIPEPTPN1MAPTMAPK1TDP1
SCHEMBL257590 0.78 LIPE (0.56) LIPEPTPN1MAPTMAPK1TDP1
SCHEMBL25817250 0.78 THRB (0.54) PTPN1MAPTMAPK1TDP1L3MBTL1
SCHEMBL24968079 0.77 L3MBTL1 (0.63) LIPEPTPN1MAPTMAPK1TDP1
SCHEMBL25817126 0.77 PTPN1 (0.45) PTPN1MAPTMAPK1TDP1L3MBTL1
SCHEMBL3317609 0.76 LIPE (0.50) LIPEMAPTLMNAHPGDENPP2
SCHEMBL2047599 0.74 PTPN1 (0.58) PTPN1MAPTMAPK1TDP1L3MBTL1
SCHEMBL5957872 0.74 LMNA (0.51) PTPN1MAPTMAPK1TDP1L3MBTL1
SCHEMBL2561377 0.74 KDM1A (0.52) LIPELMNAHPGDENPP2GLRA1
SCHEMBL31266300 0.74 KDM1A (0.52) LIPELMNAHPGDENPP2GLRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-11-21 US disclosed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 LIPE 3571/4885PTPN1 1336/4885MAPT 3879/4885
US-11820778-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 LIPE 3571/4885PTPN1 1336/4885MAPT 3879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.